Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

Panelists discuss how patient and disease factors influence the choice between ide-cel and cilta-cel for chimeric antigen receptor (CAR) T-cell therapy, the significance of adverse event profiles in clinical decision-making, the use of bridging therapy prior to infusion, and the experiences of progression rates and potential mechanisms post treatment, as well as future directions for CAR T-cell therapy in relapsed/refractory multiple myeloma.

EP: 1.Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP: 2.Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP: 3.Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP: 4.MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP: 5.Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP: 6.Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Now Viewing

EP: 7.Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP: 8.CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP: 9.Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP: 10.Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

1. Dr Ajai Chari to Dr Rossi (then open to panelists): What patient or disease factors do you weigh when deciding whether a patient should receive ide-cel vs cilta-cel?
2. Dr Ajai Chari to Dr Martin: When weighing treatment options, how heavily is the chimeric antigen receptor (CAR) T adverse effect (AE) profile considered in your clinical judgment?

• What are the similarities and differences between the AE profiles of ide-cel vs cilta-cel?

1. Dr Ajai Chari to Dr Callander: What is your approach to bridging therapy prior to CAR T-cells being infused?

• How frequently do you utilize bridging therapy? What agents are you typically using?

1. Dr Ajai Chari to Dr Raje: Of the patients you have treated with CAR T-cell therapy, what percentage of patients have progressed?

• How long until progression occurs in your experience?
• What are some possible mechanisms of release post CAR T-cell therapy?

1. Dr Ajai Chari to Dr Rossi: What are some future directions for CAR T-cell therapy in relapsed/refractory multiple myeloma?

Related Videos